ClinicalTrials.gg

Program

trastuzumab envedotin

Also written as “DP303c”, “DP303c injection” and “DP303c treatment”.

Its studies are mostly in Breast Neoplasms · Ovarian Neoplasms · Stomach Neoplasms, led by 2 companies.

Furthest: phase 3, since Jun 4, 20237 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group62 open or runningphase 3since Jun 4, 2023Mar 22, 2021none ahead
Shanghai Runshi Pharmaceutical Technology11 open or runningphase 2since Aug 21, 2024Aug 21, 2024none ahead
  • Named in CSPC Pharmaceutical Group’s own pipeline as trastuzumab envedotin, phase 4, as of Aug 20, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 22, 2021First studies: 2 phase 2 studiesNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT04826107, NCT04828616
  2. Mar 27, 2022Phase 2 study in HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT05334810 · 191 enrolled
  3. Mar 14, 2023Phase 1 study in HER2-positive Advanced Solid TumorsCSPC Pharmaceutical Group · NCT05810103 · 12 enrolled · China
  4. Jun 4, 2023Phase 3 study in HER2-positive Advanced Breast CancerCSPC Pharmaceutical Group · NCT05901935 · 420 planned
  5. Mar 1, 2024Phase 3 study in HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT06313086 · 442 planned · China
  6. Aug 21, 2024Shanghai Runshi Pharmaceutical Technology’s first study: phase 2 study in Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaNew to Shanghai Runshi Pharmaceutical TechnologyShanghai Runshi Pharmaceutical Technology · NCT06577376 · 252 planned

TargetBeta

“An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1 (IgG1) a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and site-specifically conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent mono…”NCIt, read by Claude

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06577376Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma2Not yet recruitingShanghai Runshi Pharmaceutical TechnologyAug 26, 2026252
NCT06313086HER2-positive Breast Cancer · China3RecruitingCSPC Pharmaceutical GroupDec 2025442
NCT05901935HER2-positive Advanced Breast Cancer3Not yet recruitingCSPC Pharmaceutical GroupJan 2026420
NCT05810103HER2-positive Advanced Solid Tumors · China1UNKNOWNCSPC Pharmaceutical GroupDec 23, 202312
NCT05334810HER2-positive Breast Cancer2UNKNOWNCSPC Pharmaceutical GroupDec 31, 2023191
NCT04828616Ovarian Neoplasms · China2UNKNOWNCSPC Pharmaceutical GroupJul 2023104
NCT04826107Stomach Neoplasms2UNKNOWNCSPC Pharmaceutical GroupAug 2024196

How it is read

Names in the registry

  • “DP303c”, 5 entries
  • “DP303c injection”, 1 entry
  • “DP303c treatment”, 1 entry
  • “DP303c treatment(second-line of HER2-positive)”, 1 entry
  • “DP303c treatment (third-line of HER2-positive)”, 1 entry

Codes read as this program: DP303C.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.